Citations for
1CDKN2A, TIMP3
P14ARF inhibits regional inflammation and vascularization in intervertebral disc degeneration by upregulating TIMP3.
He M, Pang J, Sun H, Zheng G, Lin Y, Ge W.
Am J Physiol Cell Physiol 318(4):C751-C761. doi: 10.1152/ajpcell.00271.2019. Epub 2020 Feb 5. 2020
2CDKN2A, PIAS1
Tumor Suppressor p14ARF Enhances IFN-γ-Activated Immune Response by Inhibiting PIAS1 via SUMOylation.
Alagu J, Itahana Y, Sim F, Chao SH, Bi X, Itahana K.
J Immunol 201(2):451-464. doi: 10.4049/jimmunol.1800327. Epub 2018 May 30. 2018
3CDKN2A, CDKN2B
Oxidative stress levels are correlated with P15 and P16 gene promoter methylation in myelodysplastic syndrome patients.
Gonçalves AC, Cortesão E, Oliveiros B, Alves V, Espadana AI, Rito L, Magalhães E, Pereira S, Pereira A, Costa JM, Mota-Vieira L, Sarmento-Ribeiro AB.
Clin Exp Med 16(3):333-43. doi: 10.1007/s10238-015-0357-2. Epub 2015 May 17. 2016
4ARF, CDKN2A, HUWE1
Syk-mediated tyrosine phosphorylation of mule promotes TNF-induced JNK activation and cell death.
Lee CK, Yang Y, Chen C, Liu J.
Oncogene 35(15):1988-95. doi: 10.1038/onc.2015.275. Epub 2015 Jul 27. 2016
5CDKN2A, VHL
Isoform-specific interactions of the von Hippel-Lindau tumor suppressor protein.
Minervini G, Mazzotta GM, Masiero A, Sartori E, Corrà S, Potenza E, Costa R, Tosatto SC.
Sci Rep 5:12605. doi: 10.1038/srep12605. 2015
6CDKN2A, KL
Ablation of the p16(INK4a) tumour suppressor reverses ageing phenotypes of klotho mice.
Sato S, Kawamata Y, Takahashi A, Imai Y, Hanyu A, Okuma A, Takasugi M, Yamakoshi K, Sorimachi H, Kanda H, Ishikawa Y, Sone S, Nishioka Y, Ohtani N, Hara E.
Nat Commun 6:7035. doi: 10.1038/ncomms8035. 2015
7CDKN2A, CDKN2B, STAT5B
Control of CD8 T cell proliferation and terminal differentiation by active STAT5 and CDKN2A/CDKN2B.
Grange M, Giordano M, Mas A, Roncagalli R, Firaguay G, Nunes JA, Ghysdael J, Schmitt-Verhulst AM, Auphan-Anezin N.
Immunology 145(4):543-57. doi: 10.1111/imm.12471. Epub 2015 Jun 15. 2015
8CDKN2A, FBXW11
S6 Kinase- and β-TrCP2-Dependent Degradation of p19Arf Is Required for Cell Proliferation.
Nakagawa T, Araki T, Nakagawa M, Hirao A, Unno M, Nakayama K.
Mol Cell Biol 35(20):3517-27. doi: 10.1128/MCB.00343-15. Epub 2015 Aug 3. 2015
9CDKN2A, CDKN2B
Aberrant promoter methylation of p15 (INK⁴b) and p16 (INK⁴a) genes may contribute to the pathogenesis of multiple myeloma: a meta-analysis.
Wang X, Zhu YB, Cui HP, Yu TT.
Tumour Biol 35(9):9035-43. doi: 10.1007/s13277-014-2054-2. Epub 2014 Jun 8. 2014
10CDKN2A, PVT1
Deletion or methylation of CDKN2A/2B and PVT1 rearrangement occur frequently in highly aggressive B-cell lymphomas harboring 8q24 abnormality.
Tsutsumi Y, Chinen Y, Sakamoto N, Nagoshi H, Nishida K, Kobayashi S, Yokokawa Y, Taki T, Sasaki N, Yamamoto-Sugitani M, Kobayashi T, Matsumoto Y, Horiike S, Kuroda J, Taniwaki M.
Leuk Lymphoma 54(12):2760-4. doi: 10.3109/10428194.2013.790543. Epub 2013 May 9. No abstract available. 2013
11CDKN2A, EEF1A2
Tumor suppressor p16(INK4a) inhibits cancer cell growth by downregulating eEF1A2 through a direct interaction.
Lee MH, Choi BY, Cho YY, Lee SY, Huang Z, Kundu JK, Kim MO, Kim DJ, Bode AM, Surh YJ, Dong Z.
J Cell Sci 126(Pt 8):1744-52. doi: 10.1242/jcs.113613. Epub 2013 Feb 26. Erratum in: J Cell Sci. 2013 Aug 15;126(Pt 16):3796. 2013
12CDKAL1, CDKN2A, CDKN2B
The relationship between five widely-evaluated variants in CDKN2A/B and CDKAL1 genes and the risk of type 2 diabetes: a meta-analysis.
Peng F, Hu D, Gu C, Li X, Li Y, Jia N, Chu S, Lin J, Niu W.
Gene 531(2):435-43. doi: 10.1016/j.gene.2013.08.075. Epub 2013 Sep 4. 2013
13CDKN2A, CDKN2B, DLC1
Inactivation of the Dlc1 gene cooperates with downregulation of p15INK4b and p16Ink4a, leading to neoplastic transformation and poor prognosis in human cancer.
Qian X, Durkin ME, Wang D, Tripathi BK, Olson L, Yang XY, Vass WC, Popescu NC, Lowy DR.
Cancer Res 72(22):5900-11. doi: 10.1158/0008-5472.CAN-12-2368. Epub 2012 Sep 25. 2012
14CDKN2A, MKRN1
Acceleration of gastric tumorigenesis through MKRN1-mediated posttranslational regulation of p14ARF.
Ko A, Shin JY, Seo J, Lee KD, Lee EW, Lee MS, Lee HW, Choi IJ, Jeong JS, Chun KH, Song J.
J Natl Cancer Inst 104(21):1660-72. doi: 10.1093/jnci/djs424. Epub 2012 Oct 25. 2012
15CDKN2A, TRADD, TRIP12
TRADD contributes to tumour suppression by regulating ULF-dependent p19Arf ubiquitylation.
Chio II, Sasaki M, Ghazarian D, Moreno J, Done S, Ueda T, Inoue S, Chang YL, Chen NJ, Mak TW.
Nat Cell Biol 14(6):625-33. doi: 10.1038/ncb2496. 2012
16CDKN2A, NMI
NMI mediates transcription-independent ARF regulation in response to cellular stresses.
Li Z, Hou J, Sun L, Wen T, Wang L, Zhao X, Xie Q, Zhang SQ.
Mol Biol Cell 23(23):4635-46. doi: 10.1091/mbc.E12-04-0304. Epub 2012 Oct 3. 2012
17CDKN2A, RNF2
RING1B ubiquitination and stability are regulated by ARF.
de Bie P, Ciechanover A.
Biochem Biophys Res Commun 426(1):49-53. doi: 10.1016/j.bbrc.2012.08.030. 2012
18CDKN2A, E2F1, HNRNPD
p16( INK4a) positively regulates cyclin D1 and E2F1 through negative control of AUF1.
Al-Khalaf HH, Colak D, Al-Saif M, Al-Bakheet A, Hendrayani SF, Al-Yousef N, Kaya N, Khabar KS, Aboussekhra A.
PLoS One 6(7):e21111. Epub 2011 Jul 20. 2011
19CDKN2A, EZH2, PDGFA, PDGFRA, PDGFRB
PDGF signalling controls age-dependent proliferation in pancreatic β-cells.
Chen H, Gu X, Liu Y, Wang J, Wirt SE, Bottino R, Schorle H, Sage J, Kim SK.
Nature 478(7369):349-55. doi: 10.1038/nature10502. 2011
20CDKN2A, CDKN2B, CDKN2B-AS1
Chromosome 9p21 SNPs Associated with Multiple Disease Phenotypes Correlate with ANRIL Expression.
Cunnington MS, Santibanez Koref M, Mayosi BM, Burn J, Keavney B.
PLoS Genet 6(4):e1000899. 2010
21CDKN2A
Variation in CDKN2A at 9p21.3 influences childhood acute lymphoblastic leukemia risk.
Sherborne AL, Hosking FJ, Prasad RB, Kumar R, Koehler R, Vijayakrishnan J, Papaemmanuil E, Bartram CR, Stanulla M, Schrappe M, Gast A, Dobbins SE, Ma Y, Sheridan E, Taylor M, Kinsey SE, Lightfoot T, Roman E, Irving JA, Allan JM, Moorman AV, Harrison CJ, Tomlinson IP, Richards S, Zimmermann M, Szalai C, Semsei AF, Erdelyi DJ, Krajinovic M, Sinnett D, Healy J, Gonzalez Neira A, Kawamata N, Ogawa S, Koeffler HP, Hemminki K, Greaves M, Houlston RS.
Nat Genet 42(6):492-4. Epub 2010 May 9.PMID: 20453839 2010
22BMI1, CDKN2A, RNF2
Identification and characterization of Bmi-1-responding element within the human p16 promoter.
Meng S, Luo M, Sun H, Yu X, Shen M, Zhang Q, Zhou R, Ju X, Tao W, Liu D, Deng H, Lu Z.
J Biol Chem 285(43):33219-29. Epub 2010 Jun 15. 2010
23CDKN2A, ZNF420
ARF-dependent regulation of ATM and p53 associated KZNF (Apak) protein activity in response to oncogenic stress.
Wang S, Tian C, Xing G, Gao M, Jiao W, Xiao T, Yin Y, He F, Zhang L.
FEBS Lett 584(18):3909-15. Epub 2010 Aug 14. 2010
24CDKN2A, SMARCA4
The chromatin remodelling factor BRG1 is a novel binding partner of the tumor suppressor p16INK4a.
Becker TM, Haferkamp S, Dijkstra MK, Scurr LL, Frausto M, Diefenbach E, Scolyer RA, Reisman DN, Mann GJ, Kefford RF, Rizos H.
Mol Cancer 8:4. 2009
25CDKN2A, XPC
ARF stimulates XPC to trigger nucleotide excision repair by regulating the repressor complex of E2F4.
Dominguez-Brauer C, Chen YJ, Brauer PM, Pimkina J, Raychaudhuri P.
EMBO Rep 10(9):1036-42. Epub 2009 Jul 31. 2009
26ASIP, CDK4, CDKN2A, CMM1, CMM2, CMM20, CMM3, CMM4, MC1R, TYR, TYRP1
Genetic risk factors for melanoma.
Meyle KD, Guldberg P.
Hum Genet 126(4):499-510. Epub 2009 Jul 8. Review. 2009
27CDKN2A, IGFBP2
IGFBP2 is a candidate biomarker for Ink4a-Arf status and a therapeutic target for high-grade gliomas.
Moore LM, Holmes KM, Smith SM, Wu Y, Tchougounova E, Uhrbom L, Sawaya R, Bruner JM, Fuller GN, Zhang W.
Proc Natl Acad Sci U S A 106(39):16675-9. Epub 2009 Sep 16.PMID: 19805356 2009
28CDKN2A, CDKN2B
Homozygous deletion of CDKN2A (p16, p14) and CDKN2B (p15) genes is a poor prognostic factor in adult but not in childhood B-lineage acute lymphoblastic leukemia: a comparative deletion and hypermethylation study.
Kim M, Yim SH, Cho NS, Kang SH, Ko DH, Oh B, Kim TY, Min HJ, She CJ, Kang HJ, Shin HY, Ahn HS, Yoon SS, Kim BK, Shin HR, Han KS, Cho HI, Lee DS.
Cancer Genet Cytogenet 195(1):59-65.PMID: 19837270 2009
29CDKN2A, CDKN2B
Different molecular mechanisms causing 9p21 deletions in acute lymphoblastic leukemia of childhood.
Novara F, Beri S, Bernardo ME, Bellazzi R, Malovini A, Ciccone R, Cometa AM, Locatelli F, Giorda R, Zuffardi O.
Hum Genet 126(4):511-20. Epub 2009 May 30.PMID: 19484265 2009
30CBX7, CDKN2A
Several distinct polycomb complexes regulate and co-localize on the INK4a tumor suppressor locus.
Maertens GN, El Messaoudi-Aubert S, Racek T, Stock JK, Nicholls J, Rodriguez-Niedenführ M, Gil J, Peters G.
PLoS One 4(7):e6380.PMID: 19636380 2009
31REM2, CDKN2A
An endothelial cell genetic screen identifies the GTPase Rem2 as a suppressor of p19ARF expression that promotes endothelial cell proliferation and angiogenesis.
Bierings R, Beato M, Edel MJ.
J Biol Chem 283(7):4408-16. Epub 2007 Dec 3. 2008
32APC, BRCA1, BRCA2, CDH1, CDKN2A, MLH1, MSH2, MSH6, PMS2, PRSS1, PTEN, RB1, SPINK1, STK11, TP53
Inherited susceptibility to common cancers.
Foulkes WD.
N Engl J Med 359(20):2143-53. No abstract available. 2008
33ANAPC1, CDKN2A
Methylation status of ANAPC1, CDKN2A and TP53 promoter genes in individuals with gastric cancer.
Lima EM, Leal MF, Burbano RR, Khayat AS, Assumpção PP, Bello MJ, Rey JA, Smith MA, Casartelli C.
Braz J Med Biol Res 41(6):539-43.PMID: 18622497 2008
34CMM2, CDKN2A, DEL9P
Multiple primary tumors associated with chromosome 9p deletion.
Lindor NM, Jalal SM, Kumar S, Lteif AN.
Am J Med Genet A 143(1):95-7. No abstract available. 2007
35CDKN2A ,CMM2
Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents.
Goldstein AM, Chan M, Harland M, Hayward NK, Demenais F, Timothy Bishop D, Azizi E, Bergman W, Bianchi-Scarra G, Bruno W, Calista D, Cannon Albright LA, Chaudru V, Chompret A, Cuellar F, Elder DE, Ghiorzo P, Gillanders EM, Gruis NA, Hansson J, Hogg D, Holland EA, Kanetsky PA, Kefford RF, Teresa Landi M, Lang J, Leachman SA, Mackie RM, Magnusson V, Mann GJ, Newton Bishop J, Palmer JM, Puig S, Puig-Butille JA, Stark M, Tsao H, Tucker MA, Whitaker L, Yakobson E.
J Med Genet 44(2):99-106. Epub 2006 Aug 11. 2007
36CDKN2A,CDKN2B
A common allele on chromosome 9 associated with coronary heart disease.
McPherson R, Pertsemlidis A, Kavaslar N, Stewart A, Roberts R, Cox DR, Hinds DA, Pennacchio LA, Tybjaerg-Hansen A, Folsom AR, Boerwinkle E, Hobbs HH, Cohen JC.
Science 316(5830):1488-91. Epub 2007 May 3. 2007
37CDKN2A,CDKN2B, ANRIL
A common variant on chromosome 9p21 affects the risk of myocardial infarction.
Helgadottir A, Thorleifsson G, Manolescu A, Gretarsdottir S, Blondal T, Jonasdottir A, Jonasdottir A, Sigurdsson A, Baker A, Palsson A, Masson G, Gudbjartsson DF, Magnusson KP, Andersen K, Levey AI, Backman VM, Matthiasdottir S, Jonsdottir T, Palsson S, Einarsdottir H, Gunnarsdottir S, Gylfason A, Vaccarino V, Hooper WC, Reilly MP, Granger CB, Austin H, Rader DJ, Shah SH, Quyyumi AA, Gulcher JR, Thorgeirsson G, Thorsteinsdottir U, Kong A, Stefansson K.
Science 316(5830):1491-3. Epub 2007 May 3. 2007
38CDKN2A, ISOC2
Identification and characterization of a novel protein ISOC2 that interacts with p16INK4a.
Huang X, Shi Z, Wang W, Bai J, Chen Z, Xu J, Zhang D, Fu S.
Biochem Biophys Res Commun 361(2):287-93. Epub 2007 Jul 16. 2007
39CDKN2A, PSMC3
TBP-1 protects the human oncosuppressor p14ARF from proteasomal degradation.
Pollice A, Sepe M, Villella VR, Tolino F, Vivo M, Calabrò V, La Mantia G.
Oncogene 26(35):5154-62. Epub 2007 Mar 5. 2007
40CDKN2A, CDKN2B, MNST
Comprehensive analysis of CDKN2A (p16INK4A/p14ARF) and CDKN2B genes in 53 melanoma index cases considered to be at heightened risk of melanoma.
Laud K, Marian C, Avril MF, Barrois M, Chompret A, Goldstein AM, Tucker MA, Clark PA, Peters G, Chaudru V, Demenais F, Spatz A, Smith MW, Lenoir GM, Bressac-de Paillerets B; French Hereditary Melanoma Study Group.
J Med Genet 43(1):39-47. Epub 2005 Jun 3. 2006
41CDKN2A, MNST
A novel type of deletion in the CDKN2A gene identified in a melanoma-prone family.
Knappskog S, Geisler J, Arnesen T, Lillehaug JR, Lonning PE.
Genes Chromosomes Cancer 45(12):1155-63. 2006
42CDKN2A, CDKN2B
The regulation of INK4/ARF in cancer and aging.
Kim WY, Sharpless NE.
Cell 127(2):265-75. Review. 2006
43CDKN1A, CDKN1B, CDKN2A, RB1
Age differences in cyclin-dependent kinase inhibitor expression and rb hyperphosphorylation in human corneal endothelial cells.
Enomoto K, Mimura T, Harris DL, Joyce NC.
Invest Ophthalmol Vis Sci 47(10):4330-40. 2006
44CDKN2A, ING1
A functional link between the tumour suppressors ARF and p33ING1.
Gonz‡lez L, Freije JM, Cal S, L—pez-Ot’n C, Serrano M, Palmero I.
Oncogene 25(37):5173-9. Epub 2006 Apr 10. 2006
45CDKN2A, UBTF
Human tumor suppressor p14ARF negatively regulates rRNA transcription and inhibits UBF1 transcription factor phosphorylation.
Ayrault O, Andrique L, Fauvin D, Eymin B, Gazzeri S, Séité P.
Oncogene 25(58):7577-86. Epub 2006 Aug 21. 2006
46CDKN2A
A common variant of CDKN2A (p16) predisposes to breast cancer.
Debniak T, Gorski B, Huzarski T, Byrski T, Cybulski C, Mackiewicz A, Gozdecka-Grodecka S, Gronwald J, Kowalska E, Haus O, Grzybowska E, Stawicka M, Swiec M, Urbanski K, Niepsuj S, Wasko B, Gozdz S, Wandzel P, Szczylik C, Surdyka D, Rozmiarek A, Zambrano O, Posmyk M, Narod SA, Lubinski J.
J Med Genet 42(10):763-5. Epub 2005 May 6. 2005
47CDKN2A, PSMC3
Functional and physical interaction of the human ARF tumor suppressor with Tat-binding protein-1.
Pollice A, Nasti V, Ronca R, Vivo M, Lo Iacono M, Calogero R, Calabrò V, La Mantia G.
J Biol Chem 279(8):6345-53. Epub 2003 Dec 9. 2004
48CDKN2A
Peculiar structure and location of 9p21 homozygous deletion breakpoints in human cancer cells.
Florl AR, Schulz WA.
Genes Chromosomes Cancer 37(2):141-8. 2003
49CDKN2A
CDKN2A as a uveal and cutaneous melanoma susceptibility gene.
Kannengiesser C, Avril MF, Spatz A, Laud K, Lenoir GM, Bressac-de-Paillerets B.
Genes Chromosomes Cancer 38(3):265-8. 2003
50CDKN2A, CDKN2B
Loss of 9p21 is embedded in a complex but consistent pattern of genomic imbalances in oral squamous cell carcinomas.
Gebhart E, Liehr T, Wolff E, Wiltfang J, Koscielny S, Ries J.
Cytogenet Genome Res 101(2):106-12. 2003
51CDKN2A,DAPK1,GSRP1
The power and the promise of DNA methylation markers.
Laird PW.
Nat Rev Cancer 3(4):253-66. Review. 2003
52CDKN2A
Germline mutation of ARF in a melanoma kindred.
Hewitt C, Lee Wu C, Evans G, Howell A, Elles RG, Jordan R, Sloan P, Read AP, Thakker N.
Hum Mol Genet 11(11):1273-9. 2002
53CDKN2A, DLC1, EXT1, MLH1, PTEN, RB1, TP53, TP73
Molecular pathogenesis of human hepatocellular carcinoma.
Thorgeirsson SS, Grisham JW.
Nat Genet 31(4):339-46. 2002
54BCL2, CDKN2A, MYC, RB1, TSG3B
Cytogenetics and molecular genetics of lung cancer.
Mitsuuchi Y, Testa JR.
Am J Med Genet 115(3):183-8. 2002
55CDKN2A, CDKN2B
Evidence of a role for the INK4 family of cyclin-dependent kinase inhibitors in ovarian granulosa cell tumors.
Arcellana-Panlilio MY, Egeler RM, Ujack E, Magliocco A, Stuart GC, Robbins SM, Coppes MJ.
Genes Chromosomes Cancer 35(2):176-81. 2002
56CDKN2A, MDM2
P14ARF promotes accumulation of SUMO-1 conjugated (H)Mdm2.
Xirodimas DP, Chisholm J, Desterro JM, Lane DP, Hay RT.
FEBS Lett 528(1-3):207-11. 2002
57SFN, CDKN2A
Coincident inactivation of 14-3-3sigma and p16INK4a is an early event in vulval squamous neoplasia.
Gasco M, Sullivan A, Repellin C, Brooks L, Farrell PJ, Tidy JA, Dunne B, Gusterson B, Evans DJ, Crook T.
Oncogene 21(12):1876-81. 2002
58CDKN2A
Genetic status of cell cycle regulators in squamous cell carcinoma of the oesophagus: the CDKN2A (p16(INK4a) and p14(ARF) ) and p53 genes are major targets for inactivation.
Smeds J, Berggren P, Ma X, Xu Z, Hemminki K, Kumar R.
Carcinogenesis 23(4):645-55. 2002
59CDKN2A, MDM2
Loss of p19ARF enhances the defects of Mdm2 overexpression in the mammary gland.
Foster CJ, Lozano G.
Oncogene 21(22):3525-31. 2002
60CDKN2A, CDKN2AIP
CARF is a novel protein that cooperates with mouse p19ARF (human p14ARF) in activating p53.
Hasan MK, Yaguchi T, Sugihara T, Kumar PK, Taira K, Reddel RR, Kaul SC, Wadhwa R.
J Biol Chem 277(40):37765-70. Epub 2002 Aug 01. 2002
61XPC, CDKN2A
Germline and somatic mutations of the INK4a-ARF gene in a xeroderma pigmentosum group C patient.
Soufir N, Ribojad M, Magnaldo T, Thibaudeau O, Delestaing G, Daya-Grosjean L, Rivet J, Sarasin A, Basset-Seguin N.
J Invest Dermatol 119(6):1355-60. 2002
62FAMMMPC, CDKN2A
Phenotypic variation in eight extended CDKN2A germline mutation familial atypical multiple mole melanoma-pancreatic carcinoma-prone families: the familial atypical mole melanoma-pancreatic carcinoma syndrome.
Lynch HT, Brand RE, Hogg D, Deters CA, Fusaro RM, Lynch JF, Liu L, Knezetic J, Lassam NJ, Goggins M, Kern S.
Cancer 94(1):84-96. 2002
63CDKN2A, FAMMMPC
CDKN2A germline mutations in familial pancreatic cancer.
Bartsch DK, Sina-Frey M, Lang S, Wild A, Gerdes B, Barth P, Kress R, Grutzmann R, Colombo-Benkmann M, Ziegler A, Hahn SA, Rothmund M, Rieder H.
Ann Surg 236(6):730-7. 2002
64CDKN2A, CDKN2B, MNST
A germline deletion of p14(ARF) but not CDKN2A in a melanoma-neural system tumour syndrome family.
Randerson-Moor JA, Harland M, Williams S, Cuthbert-Heavens D, Sheridan E, Aveyard J, Sibley K, Whitaker L, Knowles M, Newton Bishop J , Bishop DT.
Hum Mol Genet 10(1):55-62. 2001
65CDKN2A
A deep intronic mutation in CDKN2A is associated with disease in a subset of melanoma pedigrees.
Harland M, Mistry S, Bishop DT, Bishop JA.
Hum Mol Genet 10(23):2679-86. 2001
66CDKN2A
Homozygous deletion of CDKN2A (p16INK4a/p14ARF) but not within 1p36 or at other tumor suppressor loci in neuroblastoma.
Thompson PM, Maris JM, Hogarty MD, Seeger RC, Reynolds CP, Brodeur GM, White PS.
Cancer Res 61(2):679-86. 2001
67CDKN2A, ID1
The transcriptional repressor of p16/Ink4a, Id1, is up-regulated in early melanomas.
Polsky D, Young AZ, Busam KJ, Alani RM.
Cancer Res 61(16):6008-11. 2001
68CDKN2A, ETS1, ETS2, ID1
Opposing effects of Ets and Id proteins on p16INK4a expression during cellular senescence.
Ohtani N, Zebedee Z, Huot TJ, Stinson JA, Sugimoto M, Ohashi Y, Sharrocks AD, Peters G, Hara E.
Nature 409(6823):1067-70. 2001
69CDKN2A
Increased loss of chromosome 9p21 but not p16 inactivation in primary non-small cell lung cancer from smokers.
Sanchez-Cespedes M, Decker PA, Doffek KM, Esteller M, Westra WH, Alawi EA, Herman JG, Demeure MJ, Sidransky D, Ahrendt SA.
Cancer Res 61(5):2092-6. 2001
70CDKN2A, CDKN2B
Molecular analysis of the INK4A and INK4B gene loci in human breast cancer cell lines and primary carcinomas.
Bisogna M, Calvano JE, Ho GH, Orlow I, Cordon-Cardo C, Borgen PI, Van Zee KJ.
Cancer Genet Cytogenet 125(2):131-8. 2001
71BCL2, CCNA1, CCNB1, CCND1, CDKN1A, CDKN2A, MKI67, RB1
Immunohistochemical expression of p53, p21/waf1, rb, p16, cyclin D1, p27, Ki67, cyclin A, cyclin B1, bcl2, bax and bak proteins and apoptotic index in normal thymus.
Kanavaros P, Stefanaki K, Rontogianni D, Papalazarou D, Sgantzos M, Arvanitis D, Vamvouka C, Gorgoulis V, Siatitsas I, Agnantis NJ, Bai M.
Histol Histopathol 16(4):1005-12. 2001
72CDKN2A, TSG9A
Two regions of homozygous deletion clusters at chromosome band 9p21 in human lung cancer.
Hamada K, Kohno T, Takahashi M, Yamazaki M, Tashiro H, Sugawara C, Ohwada S, Sekido Y, Minna JD, Yokota J.
Genes Chromosomes Cancer 27(3):308-318 2000
73CDKN2A
p16 protein expression is associated with a poor prognosis in squamous cell carcinoma of the lung.
Huang CI, Taki T, Higashiyama M, Kohno N, Miyake M.
Br J Cancer 82(2):374-80. 2000
74CDKN2A
Germline CDKN2A mutation implicated in predisposition to multiple myeloma.
Dilworth D, Liu L, Stewart AK, Berenson JR, Lassam N, Hogg D.
Blood 95(5):1869-71. 2000
75CDKN2A
Frequent loss of 9p21 (p16(INK4A)) and other genomic imbalances in human malignant fibrous histiocytoma.
Simons A, Schepens M, Jeuken J, Sprenger S, van de Zande G, Bjerkehagen B, Forus A, Weibolt V, Molenaar I, van den Berg E, Myklebost O, Bridge J, van Kessel AG, Suijkerbuijk R.
Cancer Genet Cytogenet 118(2):89-98. 2000
76CDKN2A
A single genetic origin for the G101W CDKN2A mutation in 20 melanoma-prone families.
Ciotti P, Struewing JP, Mantelli M, Chompret A, Avril MF, Santi PL, Tucker MA, Bianchi-Scarra G, Bressac-de Paillerets B, Goldstein AM.
Am J Hum Genet 67(2):311-9. 2000
77CDKN2A
Alterations of the INK4a/ARF locus in human intracranial germ cell tumors.
Iwato M, Tachibana O, Tohma Y, Arakawa Y, Nitta H, Hasegawa M, Yamashita J, Hayashi Y.
Cancer Res 60(8):2113-5. 2000
78CDKN2A, CDKN2B
Analysis of the p16INK4, p14ARF, p15, TP53, and MDM2 genes and their prognostic implications in osteosarcoma and Ewing sarcoma.
Tsuchiya T, Sekine K, Hinohara S, Namiki T, Nobori T, Kaneko Y.
Cancer Genet Cytogenet 120(2):91-8. 2000
79CDKN2A
Allelic deletion at 9p21-22 in primary cutaneous CD30(+) large cell lymphoma.
Boni R, Xin H, Kamarashev J, Utzinger E, Dummer R, Kempf W, Kutzner H, Burg G.
J Invest Dermatol 115(6):1104-7. 2000
80CDKN2A, RB1
Frequent alterations in the expression of tumor suppressor genes p16INK4A and pRb in esophageal squamous cell carcinoma in the Indian population.
Ralhan R, Mathew R, Arora S, Bahl R, Shukla NK, Mathur M.
J Cancer Res Clin Oncol 126(11):655-60. 2000
81FAMMMPC, CDKN2A
Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden).
Vasen HF, Gruis NA, Frants RR, van Der Velden PA, Hille ET, Bergman W.
Int J Cancer 87(6):809-11. 2000
82CDKN2A, CMM2
Mutation of the CDKN2A 5' UTR creates an aberrant initiation codon and predisposes to melanoma.
Liu L, Dilworth D, Gao L, Monzon J, Summers A, Lassam N, Hogg D.
Nat Genet 21 : 128-132. 1999
83CDK4, CDKN2A
CDK4 gene amplification in osteosarcoma : reciprocal relationship with INK4A gene alterations and mapping of 12q13 amplicons.
Wei G, et al.
Int J Cancer 80 : 199-204. 1999
84CDKN2A, CDKN2B
Alterations of INK4A and INK4B genes in adult soft tissue sarcomas: effect on survival.
Orlow I, et al.
J Natl Cancer Inst 91(1):73-9. 1999
85CDKN2A
p16(INK4) is inactivated by extensive CpG methylation in human hepatocellular carcinoma.
Matsuda Y, et al.
Gastroenterology 116(2):394-400. 1999
86CDKN2A, CDKN2B, IFN1@, TSG9A
Identification and characterization of a homozygous deletion found in ovarian ascites by representational difference analysis.
Watson JEV, et al.
Genome Res 9(3):226-33. 1999
87CDKN2A
High frequency of p16INK4A gene alterations in hepatocellular carcinoma.
Liew CT, et al.
Oncogene 18(3):789-95. 1999
88CDKN2A, CDKN2C
Identification of functional elements of p18INK4C essential for binding and inhibition of cyclin-dependent kinase (CDK) 4 and CDK6.
Noh SJ, et al.
Cancer Res 59(3):558-64. 1999
89RB1, CDKN2A
Level of retinoblastoma protein expression correlates with p16 (MTS-1/INK4A/CDKN2) status in bladder cancer.
Benedict WF, et al.
Oncogene 18(5):1197-203. 1999
90B4GALT1, CDKN2A
Down-regulation of beta1,4-galactosyltransferase gene expression by cell-cycle suppressor gene p16.
Zhang SW, et al.
Biochim Biophys Acta 1444(1):49-54. 1999
91CDKN2A
Analysis of p16 (CDKN2/MTS-1/INK4A) alterations in primary sporadic uveal melanoma.
Merbs SL, et al.
Invest Ophthalmol Vis Sci 40(3):779-83. 1999
92CDKN2A
The INK4A/ARF locus and its two gene products.
Sharpless NE, et al.
Curr Opin Genet Dev 9(1):22-30. Review. 1999
93CDKN2A, CDKN2B
Acquisition of p16(INK4A) and p15(INK4B) gene abnormalities between initial diagnosis and relapse in children with acute lymphoblastic leukemia.
Maloney KW, et al.
Blood 93(7):2380-5. 1999
94CDKN2A
p16 mutation frequency and clinical correlation in head and neck cancer.
Danahey DG, et al.
Acta Otolaryngol (Stockh) 119(2):285-8. 1999
95CDK4, CDKN2A
Normal repair of ultraviolet radiation-induced DNA damage in familial melanoma without CDKN2A or CDK4 gene mutation.
Shannon JA, et al.
Melanoma Res 9(2):133-7. 1999
96CDKN2A
p16/MTS1/INK4A gene is frequently inactivated by hypermethylation in childhood acute lymphoblastic leukemia with 11q23 translocation.
Nakamura M, et al.
Leukemia 13(6):884-90. 1999
97CDKN2A
Tumor suppressor gene p16 (CDKN2A) mutation status and promoter inactivation in head and neck cancer.
Riese U, et al.
Int J Mol Med 4(1):61-5. 1999
98CDKN2A
Chromosome band 9p21 is frequently altered in malignant peripheral nerve sheath tumors: Studies of CDKN2A and other genes of the pRB pathway.
Berner JM, et al.
Genes Chromosomes Cancer 26(2):151-160 1999
99CDKN2A
A major quantitative-trait locus for mole density is linked to the familial melanoma gene CDKN2A: a maximum-likelihood combined linkage and association analysis in twins and their sibs.
Zhu G, et al.
Am J Hum Genet 65(2):483-92 1999
100CDKN2A, CDKN2B
Functional evidence for a role of combined CDKN2A (p16-p14(ARF))/CDKN2B (p15) gene inactivation in malignant gliomas.
Simon M, Koster G, Menon AG, Schramm J.
Acta Neuropathol (Berl) 98(5):444-52 1999
101CDK4, CDKN2A, CMM3
Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France.
Soufir N, Avril MF, Chompret A, Demenais F, Bombled J, Spatz A, Stoppa-Lyonnet D, Benard J, Bressac-de Paillerets B.
Hum Mol Genet 7(2):209-16. 1998
102CDKN2A, MTAP
The methylthioadenosine phosphorylase gene is frequently co-deleted with the p16INK4a a gene in acute type adult T-cell leukemia.
Hori Y, Hori H, Yamada Y, Carrera CJ, Tomonaga M, Kamihira S, Carson DA, Nobori T.
Int J Cancer 75(1):51-6. 1998
103CDKN2A, CMM2
CDKN2A mutations in multiple primary melanomas.
Monzon J, et al.
N Engl J Med 338 : 879-887. 1998
104CDKN2A
p16(INK4a) gene inactivation by deletions, mutations, and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin's lymphomas.
Pinyol M, et al.
Blood 91 : 2977-2984. 1998
105CDKN2A, CDKN2B
Virtually 100% of melanoma cell lines harbor alterations at the DNA level within CDKN2A, CDKN2B, or one of their downstream targets.
Walker GJ, et al.
Genes Chromosomes Cancer 22 : 157-163. 1998
106CDKN2A
CDKN2A gene deletions and loss of p16 expression occur in osteosarcomas that lack RB alterations.
Nielsen GP, et al.
Am J Pathol 153 : 159-163. 1998
107CDKN2A, CDKN2B, CMM2, TSG9A
Mutations of p16 and p15 tumor suppressor genes and replication errors contribute independently to the pathogenesis of sporadic malignant melanoma.
Matsumura Y, et al.
Arch Dermatol Res 290 : 175-180. 1998
108CDKN2A, CDKN2B, CDKN2C, CDKN2D
Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells.
Drexler HG.
Leukemia 12 : 845-859. 1998
109CDKN2A
The alternative product from the human CDKN2A locus, p14ARF, participates in a regulatory feedback loop with p53 and MDM2.
Stott FJ, Bates S, James MC, McConnell BB, Starborg M, Brookes S, Palmero I, Ryan K, Hara E, Vousden KH, Peters G.
EMBO J 17 : 5001-5014. 1998
110CDKN2A
Structural basis for inhibition of the cyclin-dependent kinase Cdk6 by the tumour suppressor p16INK4a.
Russo AA, et al.
Nature 395 : 237-243. 1998
111CDKN2A
The human p19ARF protein encoded by the beta transcript of the p16INK4a gene is frequently lost in small cell lung cancer.
Gazzeri S, Della Valle V, Chaussade L, Brambilla C, Larsen CJ, Brambilla E.
Cancer Res 58 : 3926-3931. 1998
112CDKN2A, TSG9A
Alteration of the CDKN2A gene in pancreatic cancers : is it a late event in the progression of pancreatic cancer ?
Sugimoto Y, et al.
Int J Oncol 13 : 669-676. 1998
113CDKN1A, CDKN2A
Mutation of p16, p21 or cyclin dependent kinase 4 is rare in acute lymphoblastic leukaemia.
Qari MH, et al.
Br J Haematol 103 : 467-472. 1998
114CDKN2A, CDKN2B, HLF, TCF3
Different patterns of homozygous p16INK4A and P15INK4B deletions in childhood acute lymphoblastic leukemias containing distinct E2A translocations.
Maloney KW, et al.
Leukemia 12 : 1417-1421. 1998
115CDKN2A
Inactivation of the p16 (INK4A) tumor-suppressor gene in pancreatic duct lesions : loss of intranuclear expression.
Wilentz RE, Geradts J, Maynard R, Offerhaus GJ, Kang M, Goggins M, Yeo CJ, Kern SE, Hruban RH.
Cancer Res 58 : 4740-4744. 1998
116CDKN2A
p53 and p16/CDKN2 gene mutations in esophageal tumors from a high-incidence area in South Africa.
Gamieldien W, Victor TC, Mugwanya D, Stepien A, Gelderblom WC, Marasas WF, Geiger DH, van Helden PD.
Int J Cancer 78 : 544-549. 1998
117CDKN2A
Genetic and epigenetic alterations of the cyclin-dependent kinase inhibitors p15INK4b and p16INK4a in human thyroid carcinoma cell lines and primary thryoid carcinomas.
Elisei R, et al.
Cancer 83 : 2185-2193. 1998
118CDKN2A
The p16 (CDKN2A) gene is involved in the growth of neuroblastoma cells and its expression is associated with prognosis of neuroblastoma patients.
Takita J, et al.
Oncogene 17 : 3137-3143. 1998
119CDKN2A
Deletion of the p16 gene and microsatellite instability in carcinoma arising in pleomorphic adenoma of the parotid gland.
Suzuki H, et al.
Diagn Mol Pathol 7(4):224-31. 1998
120CDKN2A, TUSC1
Alterations of p16-pRb pathway and chromosome locus 9p21-22 in sporadic invasive breast carcinomas.
Gorgoulis VG, et al.
Mol Med 4(12):807-22. 1998
121CDKN2A
The INK4a/ARF tumor suppressor: one gene--two products--two pathways.
Chin L, Pomerantz J, DePinho RA.
Trends Biochem Sci 23(8):291-6. Review 1998
122CDKN2A, CDKN2B, MNST
Germ-line deletion involving the INK4 locus in familial proneness to melanoma and nervous system tumors.
Bahuau M, Vidaud D, Jenkins RB, Bieche I, Kimmel DW, Assouline B, Smith JS, Alderete B, Cayuela JM, Harpey JP, Caille B, Vidaud M.
Cancer Res 58(11):2298-303. 1998
123CDKN1A, CDKN2A, TSG9A
Deletions and loss of expression of P16INK4a and P21Waf1 genes are associated with agressive variants of mantle cell lymphomas.
Pinyol M, et al.
Blood 89 : 272-280. 1997
124CDKN2A, TSG9A
Point mutations can inactivate in vitro and in vivo activities of p16INK4a/CDKN2A in human glioma.
Arap W, et al.
Oncogene 14 : 603-609. 1997
125CDKN2A, TSG9A
Mutations of the INK4a locus in squamous cell carcinomas of human skin.
Kubo Y, et al.
Biochem Biophys Res Commun 232 : 38-41. 1997
126CDKN2A, CDKN2B, CMM2
Affected members of melanoma-prone families with linkage to 9p21 but lacking mutations in CDKN2A do not harbor mutations in the coding regions of either CDKN2B or p19ARF.
Liu L, et al.
Genes Chromosomes Cancer 19 : 52-54. 1997
127CDKN2A, TSG9A
Deletional, mutational, and methylation analyses of CDKN2 (p16/MTS1) in primary and metastatic prostate cancer.
Jarrard DF, Bova GS, Ewing CM, Pin SS, Nguyen SH, Baylin SB, Cairns P, Sidransky D, Herman JG, Isaacs WB.
Genes Chromosomes Cancer 19(2):90-6. 1997
128CDKN2A, TSG9A
Frequent homozygous deletion of cyclin-dependent kinase inhibitor 2 (MTS1, p16) in superficial bladder cancer detected by fluorescence in situ hybridization.
Balazs M, Carroll P, Kerschmann R, Sauter G, Waldman FM.
Genes Chromosomes Cancer 19(2):84-9. 1997
129CDKN2A, CMM2, TSG9A
Loss of expression of the p16INK4/CDKN2 gene in cutaneous malignant melanoma correlates with tumor cell proliferation and invasive stage.
Talve L, Sauroja I, Collan Y, Punnonen K, Ekfors T.
Int J Cancer 74(3):255-9. 1997
130CDKN2A, CDKN2B, TSG9A
Chromosome 9p deletions in invasive and noninvasive nonfunctional pituitary adenomas: the deleted region involves markers outside of the MTS1 and MTS2 genes.
Farrell WE, Simpson DJ, Bicknell JE, Talbot AJ, Bates AS, Clayton RN.
Cancer Res 57(13):2703-9. 1997
131CDKN2A, TSG9A
Mutation of CDKN2 is infrequently detected in myelodysplastic syndrome.
Kaneko H, Horiike S, Nakao M, Yokota S, Sasai Y, Iwai T, Nakagawa H, Fujii H, Taniwaki M, Kashima K, Misawa S.
Leukemia 11(8):1391-2. 1997
132CDKN2A
Germline mutations of the CDKN2 gene in UK melanoma families.
Harland M, Meloni R, Gruis N, Pinney E, Brookes S, Spurr NK, Frischauf AM, Bataille V, Peters G, Cuzick J, Selby P, Bishop DT, Bishop JN.
Hum Mol Genet 6(12):2061-7. 1997
133CDKN2A
Inherited susceptibility to several cancers but absence of linkage between dysplastic nevus syndrome and CDKN2A in a melanoma family with a mutation in the CDKN2A (P16INK4A) gene.
Puig S, Ruiz A, Castel T, Volpini V, Malvehy J, Cardellach F, Lynch M, Mascaro JM, Estivill X.
Hum Genet 101(3):359-64. 1997
134CDKN2A, TSG9A
p16MTS1/CDK4I mutations and concomitant loss of heterozygosity at 9p21-23 are frequent events in squamous cell carcinoma of the larynx.
Jares P, Fernandez PL, Nadal A, Cazorla M, Hernandez L, Pinyol M, Hernandez S, Traserra J, Cardesa A, Campo E.
Oncogene 15(12):1445-53. 1997
135CDKN2A, TSG1G, TSG6F, TSG10A, KLF6, TSG14B, LOH18CR1
Analysis of genomic alterations in benign, atypical, and anaplastic meningiomas : toward a genetic model of meningioma progression.
Weber RG, Bostrom J, Wolter M, Baudis M, Collins VP, Reifenberger G, Lichter P.
Proc Natl Acad Sci U S A 94(26):14719-24. 1997
136CDKN2A, CDKN2B, TSG9A
Disruption of the multiple tumor suppressor gene MTS1/p16(INK4a)/CDKN2 by illegitimate V(D)J recombinase activity in T-cell acute lymphoblastic leukemias.
Cayuela JM, Gardie B, Sigaux F.
Blood 90(9):3720-6. 1997
137CDKN2A
Cancer-associated mutations at the INK4a locus cancel cell cycle arrest by p16INK4a but not by the alternative reading frame protein p19ARF.
Quelle DE, et al.
Proc Natl Acad Sci U S A 94 : 669-673. 1997
138CDKN2A
Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF.
Kamijo T, et al.
Cell 91 : 649-659. 1997
139CDKN2A
Compilation of somatic mutations of the CDKN2 gene in human cancers : non-random distribution of base substitutions.
Pollock PM, et al.
Genes Chromosomes Cancer 15 : 77-88. 1996
140CDKN2A, TSG9A
Deletion mapping indicates that MTS1 is the target of frequent deletions at chromosome 9p21 in paediatric acute lymphoblastic leukaemias.
Guidal-Giroux C, et al.
Br J Haematol 92 : 410-419. 1996
141CDKN2A, CDKN2B, CDKN2C, TSG9A
Analysis of cyclin-dependent kinase inhibitor genes (CDKN2A, CDKN2B, andCDKN2C) in childhood rhabdomyosarcoma.
Iolascon A, et al.
Genes Chromosomes Cancer 15 : 217-222. 1996
142CDKN2A, TSG9A
Homozygous deletions of the CDKN2/p16 gene in dural hemangiopericytomas.
Ono Y, et al.
Acta Neuropathol 91 : 221-225. 1996
143D9S974, D9S975, D9S976, D9S977, D9S978, CDKN2A, CDKN2B, TSG9A
Deletion mapping of chromosome region 9p21-p22 surrounding the CDKN2 locus in melanoma.
Ohta M, et al.
Int J Cancer 65 : 762-767. 1996
144CDKN2A, TSG9A
Frequent loss of the P16INK4a gene product in human pituitary tumors.
Woloschak M, et al.
Cancer Res 56 : 2493-2496. 1996
145CDKN2A
p16INK4A gene homozygous deletions in human acute leukaemias with alterations of chromosome 9.
Faienza MF, et al.
Br J Haematol 93 : 632-636. 1996
146CDKN2A
CDNK2A (p16INK4A) somatic and germline mutations.
Smith-Sšrensen B, et al.
Hum Mutat 7 : 294-303. 1996
147CDKN2A, TSG9A
Hypermethylation of the p16 gene in nasopharyngeal carcinoma.
Lo KW, et al.
Cancer Res 56 : 2721-2725. 1996
148CDK4, CDKN2A, CMM2, TSG9A
Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma : analysis of a clinic-based population.
Fitzgerald MG, et al.
Proc Natl Acad Sci U S A 93 : 8541-8545. 1996
149CDKN2A, CDKN2B, CMM2, TSG9A
Chromosome 9 related aberrations and deletions of the CDKN2 and MTS2 putative tumor suppressor genes in human chondrosarcomas.
Jagasia AA, et al.
Cancer Lett 105 : 91-103. 1996
150CDKN2A, CMM2, TSG9A
Infrequent mutation of p16INK4 in sporadic melanoma.
Healy E, et al.
J Invest Dermatol 107 : 318-321. 1996
151CDKN2A, TSG9A
Hypermethylation of the CpG island of p16/CDKN2 correlates with gene inactivation in gliomas.
Fueyo J, et al.
Oncogene 13 : 1615-1619. 1996
152CDKN2A
Informative Mspl polymorphism adjacent to exon 3 of the p16INK4 (MTS1) gene.
Chaubert P, et al.
Mol Cell Probes 10 : 467-468. 1996
153CDKN2A
MTS1 gene mutations in archival oral squamous cell carcinomas.
Dawson CD, et al.
J Oral Pathol Med 25 : 541-546. 1996
154CDKN2A, TSG9A
Allelic loss of 9p21 and mutation of the CDKN2/p16 gene develop as early lesions during neoplastic progression in Barrett's esophagus.
Barrett MT, et al.
Oncogene 13 : 1867-1873. 1996
155CDKN2A, TSG9A
MTS-1 (CDKN2) tumor suppressor gene deletions are a frequent event in esophagus squamous cancer and pancreatic adenocarcinoma cell lines.
Liu Q, et al.
Oncogene 10 : 619-622. 1995
156CDKN2A, CDKN2B, TSG9A
Deletion of CDK4 inhibitor genes P15 and P16 in non-Hodgkin's lymphoma. (abstr)
Koduru PRK, et al.
Blood 86(8):2900-5. 1995
157TSG9A, CDKN2A
Refined mapping of genomic rearrangements involving the short arm of chromosome 9 in acute lymphoblastic leukemias and other hematologic malignancies.
Dreyling MH, et al.
Blood 86 : 1931-1938. 1995
158CDKN2A
Mutations of the CDKN2/p16ink4 gene in Australian melanoma kindreds.
Walker GJ, Hussussian CJ, Flores JF, Glendening JM, Haluska FG, Dracopoli NC, Hayward NK, Fountain JW.
Hum Mol Genet 4(10):1845-52. 1995
159TSG9A, CDKN2A, CDKN2B
Intragenic mutations of CDKN2B and CDKN2A in primary human esophageal cancers.
Suzuki H, Zhou X, Yin J, Lei J, Jiang HY, Suzuki Y, Chan T, Hannon GJ, Mergner WJ, Abraham JM, et al.
Hum Mol Genet 4(10):1883-7. 1995
160TSG9A, CDKN2A, CMM2
Frequency of homozygous deletion at p16/CDKN2 in primary human tumours.
Cairns P, Polascik TJ, Eby Y, Tokino K, Califano J, Merlo A, Mao L, Herath J, Jenkins R, Westra W, et al.
Nat Genet 11 : 210-212. 1995
161CDKN2D, CDKN2A, CDKN2B
Molecular cloning, expression pattern, and chromosomal localization of human CDKN2D/INK4d an inhibitor of cyclin D-dependent kinases.
Okuda T, Hirai H, Valentine VA, Shurtleff SA, Kidd VJ, Lahti JM, Sherr CJ, Downing JR.
Genomics 29(3):623-30. 1995
162CDKN2A, TSG9B
Detailed deletion mapping of chromosome 9p and p16 gene alterations in human borderline and invasive epithelial ovarian tumors.
Rodabaugh KJ, et al.
Oncogene 11 : 1249-1254. 1995
163CDKN2A, TSG9A
Frequent mutations of CDKN2 in primary pancreatic adenocarcinomas.
Bartsch D, et al.
Genes Chromosomes Cancer 14 : 189-195. 1995
164CDKN2A, CMM2, TSG9A
Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations.
Goldstein AM, Fraser MC, Struewing JP, Hussussian CJ, Ranade K, Zametkin DP, Fontaine LS, Organic SM, Dracopoli NC, Clark WH Jr, et al.
N Engl J Med 333 : 970-974. 1995
165CDKN2A, CMM2, TSG9A
A familial syndrome of pancreatic cancer and melanoma with a mutation inthe CDKN2 tumor-suppressor gene.
Whelan AJ, Bartsch D, Goodfellow PJ.
N Engl J Med 333 : 975-977. 1995
166CDKN2A, TSG9A
Analysis of the p16 gene, CDKN2, in 17 Australian melanoma kindreds.
Holland EA, et al.
Oncogene 11 : 2289-2294. 1995
167CDKN2A, TSG9A
CDKN2 gene deletion is not found in chronic lymphoid leukaemias of B- and T-cell origin but is frequent in acute lymphoblastic leukaemia.
Schršder M, et al.
Br J Haematol 91 : 865-870. 1995
168CDKN2A, TSG9A
Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers.
Herman JG, et al.
Cancer Res 55 : 4525-4530. 1995
169CDKN2A, CDKN2B, TSG9A
Loss of heterozygosity at 9p21 loci and mutations of the MTS1 and MTS2 genes in human lung cancers.
Shimizu T, et al.
Int J Cancer 63 : 616-620. 1995
170CDKN2A, TSG9A
Deletions and rearrangement of CDKN2 in lymphoid malignancy.
Stranks G, et al.
Blood 85 : 893-901. 1995
171CMM2, CDKN2A
Mutations associated with familial melanoma impair p16ink4 function.
Ranade K, et al.
Nat Genet 10 : 114-116. 1995
172TSG9A, CDKN2A
Homozygous deletions and loss of expression of the CDKN2 gene occur frequently in head and neck squamous cell carcinoma cell lines but infrequently in primary tumors.
Lydiatt WM, et al.
Genes Chromosomes Cancer 13 : 94-98. 1995
173CDKN2A, RB1, CCND1
Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16.
Lukas J, et al.
Nature 375 : 503-506. 1995
174CDKN2A, TSG9A
Frequent loss of the cyclin-dependent kinase-4 inhibitor gene in human gliomas.
Gomi A, et al.
Jpn J Cancer Res 86 : 342-346. 1995
175CDKN2A, CMM2
Germline p16INK4A mutation and protein dysfunction in a family with inherited melanoma.
Liu L, et al.
Oncogene 11 : 405-412. 1995
176TSG9A, CDKN2A
p16 (CDKN2) is a major deletion target at 9p21 in bladder cancer.
Williamson MP, et al.
Hum Mol Genet 4 : 1569-1577. 1995
177CDKN2A, TSG9A, CMM2
Chromosome 9p deletions in cutaneous malignant melanoma tumors : The minimal deleted region involves markers outside the p16 (CDKN2) gene.
Puig S, et al.
Am J Hum Genet 57 : 395-402. 1995
178TSG9A, CDKN2A, CDKN2B
Codeletion of p15 and p16 in primary malignant mesothelioma.
Xiao S, et al.
Oncogene 11 : 511-515. 1995
179TSG9A, CDKN2A, S100A4
Frequent loss of heterozygosity on chromosome 9, and low incidence of mutations of cyclin-dependent kinase inhibitors p15 (MTS2) and p16 (MTS1) genes in gliomas.
Li YJ, et al.
Oncogene 11 : 597-600. 1995
180CMM2, CDKN2A
Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds.
Gruis NA, et al.
Nat Genet 10 : 351-353. 1995
181CDKN2A, TSG9A
Chromosome 9p allelic loss and p16/CDKN2 in breast cancer and evidence of p16 inactivation in immortal breast epithelial cells.
Brenner AJ, et al.
Cancer Res 55 : 2892-2895. 1995
182CMM2, CDKN2A
Mutation frequency of the p16/CDKN2 gene in primary cancers in the upper digestive tract.
Igaki H, et al.
Cancer Res 55 : 3421-3423. 1995
183CDKN2A
A new type of p16INK4/MTS1 gene transcript expressed in B-cell malignancies.
Duro D, et al.
Oncogene 11 : 21-29. 1995
184CDKN2A, TSG9A
Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest.
Quelle DE, et al.
Cell 83(6):993-1000. 1995
185CDKN2A
Complex structure and regulation of the P16 (MTS1) locus.
Stone S, Jiang P, Dayananth P, Tavtigian SV, Katcher H, Parry D, Peters G, Kamb A.
Cancer Res 55(14):2988-94. 1995
186CDKN2A
A novel p16INK4A transcript.
Mao L, Merlo A, Bedi G, Shapiro GI, Edwards CD, Rollins BJ, Sidransky D.
Cancer Res 55(14):2995-7. 1995
187CDKN2A
Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers.
Nobori T, et al.
Nature 368 : 753-756. 1994
188CDKN2A, TSG9A
Rates of p16 (MTS1) mutations in primary tumors with 9p loss.
Cairns P, et al.
Science 265 : 415-416. 1994
189CDKN2A
Frequent somatic mutation of the MTS1/CDK4I (multiple tumor suppressor/cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma.
Mori T, et al.
Cancer Res 54 : 3396-3397. 1994
190CDKN2A, CMM2
Germline p16 mutations in familial melanoma.
Hussussian CJ, et al.
Nat Genet 8 : 15-21. 1994
191CDKN2A, TSG9A
Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma.
Caldas C, et al.
Nat Genet 8 : 27-32. 1994
192CDKN2A, TSG9A
MTS1/CDKN2 gene mutations are rare in primary human astrocytomas with allelic loss of chromosome 9p.
Ueki K, et al.
Hum Mol Genet 3 : 1841-1845. 1994
193CDKN2A, TSG9A
Higher frequency of alterations in the p16/CDKN2 gene in squamous cell carcinoma cell lines than in primary tumors of the head and neck.
Zhang SY, et al.
Cancer Res 54 : 5050-5053. 1994
194CDKN2A, TSG9A
The MTS1 gene is frequently mutated in primary human esophageal tumors.
Zhou X, et al.
Oncogene 9 : 3737-3741. 1994
195CDKN2A, D9S598
Dinucleotide repeat polymorphism adjacent to CDKN2.
Herbst RA, et al.
Hum Mol Genet 3 : 2265. 1994
196CDKN2A, TSG9A
Homozygous loss of the cyclin-dependent kinase 4-inhibitor (p16) gene in human leukemias.
Ogawa S, et al.
Blood 84 : 2431-2435. 1994
197CDKN2A, CMM2
Penetrance and expressivity of the chromosome 9p melanoma susceptibility locus (MLM).
Cannon-Albright LA, et al.
Cancer Res 54 : 6041-6044. 1994
198CDKN2A, TSG9A
Somatic mutations of the MTS (Multiple Tumor Suppressor) 1/CDK4I(Cyclin-Dependent Kinase-4 Inhibitor) gene in human primary non-small cell lung carcinomas.
Hayashi N, et al.
Biochem Biophys Res Commun 202 : 1426-1430. 1994
199CDKN2A, CDKN2B
Candidate tumor-suppressor genes MTS1 (p16ink4A) and MTS2 (p15ink4B) display frequent homozygous deletions in primary cells from T-but not from B-cell lineage acute lymphoblastic leukemias.
Hebert J, et al.
Blood 84 : 4038-4044. 1994
200CDKN2A, TSG9A, CMM2
P16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma.
Cheng JQ, et al.
Cancer Res 54 : 5547-5551. 1994
201CDKN2A, TSG9A, CDK4
CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas.
Schmidt EE, et al.
Cancer Res 54 : 6321-6324. 1994
202CDKN2A, TSG9A
Mutation rate of the CDKN2 gene in malignant gliomas.
Giani C, et al.
Cancer Res 54 : 6338-6339. 1994
203TSG9A, CDKN2A, CDKN2B
Deletion of p16 and p15 genes in brain tumors.
Jen J, et al.
Cancer Res 54 : 6353-6358. 1994
204CDKN2A
A cell cycle regulator potentially involved in genesis of many tumor types.
Kamb A, et al.
Science 264 : 436-440. 1994
205CMM2, CDKN2A
Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus.
Kamb A, et al.
Nat Genet 8 : 22-26. 1994
206CDKN2A
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano M, et al.
Nature 366 : 704-707. 1993